<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Fri, 06 Oct 2023 08:10:49 +0000</lastbuilddate>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Brain endothelium: a nexus for cerebral small vessel disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37798089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 29:ehad526. doi: 10.1093/eurheartj/ehad526. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37798089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37798089</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad526>10.1093/eurheartj/ehad526</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37798089</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Martin Dichgans</dc:creator>
<dc:creator>Frank M Faraci</dc:creator>
<dc:creator>BRENDA Network</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Brain endothelium: a nexus for cerebral small vessel disease</dc:title>
<dc:identifier>pmid:37798089</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad526</dc:identifier>
</item>
<item>
<title>The European Society of Cardiology working group on cardiovascular pharmacotherapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37796825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 4:ehad651. doi: 10.1093/eurheartj/ehad651. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37796825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37796825</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad651>10.1093/eurheartj/ehad651</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37796825</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Juan Carlos Kaski</dc:creator>
<dc:creator>Alexander Niessner</dc:creator>
<dc:creator>Dobromir Dobrev</dc:creator>
<dc:creator>Bianca Rocca</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The European Society of Cardiology working group on cardiovascular pharmacotherapy</dc:title>
<dc:identifier>pmid:37796825</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad651</dc:identifier>
</item>
<item>
<title>Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37795986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The 2022 ESC model performed better than the 2014 ESC model with especially improved sensitivity. LGE enabled further risk stratification based on current guidelines.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 5:ehad581. doi: 10.1093/eurheartj/ehad581. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Identifying patients with hypertrophic cardiomyopathy (HCM) who are candidates for implantable cardioverter defibrillator (ICD) implantation in primary prevention for sudden cardiac death (SCD) is crucial. The aim of this study was to externally validate the 2022 European Society of Cardiology (ESC) model and other guideline-based ICD class of recommendation (ICD-COR) models and explore the utility of late gadolinium enhancement (LGE) in further risk stratification.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Seven hundred and seventy-four consecutive patients who underwent cardiac magnetic resonance imaging were retrospectively enrolled.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Forty-six (5.9%) patients reached the SCD-related endpoint during 7.4 ± 2.5 years of follow-up. Patients suffering from SCD had higher ESC Risk-SCD score (4.3 ± 2.4% vs. 2.8 ± 2.1%, P &lt; .001) and LGE extent (13.7 ± 9.4% vs. 4.9 ± 6.6%, P &lt; .001). Compared with the 2014 ESC model, the 2022 ESC model showed increased area under the curve (.76 vs. .63), sensitivity (76.1% vs. 43.5%), positive predictive value (16.8% vs. 13.6%), and negative predictive value (98.1% vs. 95.9%). The C-statistics for SCD prediction of 2011 American College of Cardiology (ACC)/American Heart Association (AHA), 2014 ESC, 2020 AHA/ACC, and 2022 ESC models were .68, .64, .76 and .78, respectively. Furthermore, in patients without extensive LGE, LGE ≥5% was responsible for seven-fold SCD risk after multivariable adjustment. Whether in ICD-COR II or ICD-COR III, patients with LGE ≥5% and &lt;15% showed significantly worse prognosis than those with LGE &lt;5% (all P &lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The 2022 ESC model performed better than the 2014 ESC model with especially improved sensitivity. LGE enabled further risk stratification based on current guidelines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37795986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37795986</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad581>10.1093/eurheartj/ehad581</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37795986</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jiaxin Wang</dc:creator>
<dc:creator>Shujuan Yang</dc:creator>
<dc:creator>Xuan Ma</dc:creator>
<dc:creator>Kankan Zhao</dc:creator>
<dc:creator>Kai Yang</dc:creator>
<dc:creator>Shiqin Yu</dc:creator>
<dc:creator>Gang Yin</dc:creator>
<dc:creator>Zhixiang Dong</dc:creator>
<dc:creator>Yanyan Song</dc:creator>
<dc:creator>Chen Cui</dc:creator>
<dc:creator>Jinghui Li</dc:creator>
<dc:creator>Chuangshi Wang</dc:creator>
<dc:creator>Jun Hao</dc:creator>
<dc:creator>Minjie Lu</dc:creator>
<dc:creator>Xiuyu Chen</dc:creator>
<dc:creator>Shihua Zhao</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines</dc:title>
<dc:identifier>pmid:37795986</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad581</dc:identifier>
</item>
<item>
<title>Nondental Invasive Procedures and Risk of Infective Endocarditis: Time for a Revisit: A Science Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37795631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>There have been no published prospective randomized clinical trials that have: (1) established an association between invasive dental and nondental invasive procedures and risk of infective endocarditis; or (2) defined the efficacy and safety of antibiotic prophylaxis administered in the setting of invasive procedures in the prevention of infective endocarditis in high-risk patients. Moreover, previous observational studies that examined the association of nondental invasive procedures with the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 5. doi: 10.1161/CIR.0000000000001180. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There have been no published prospective randomized clinical trials that have: (1) established an association between invasive dental and nondental invasive procedures and risk of infective endocarditis; or (2) defined the efficacy and safety of antibiotic prophylaxis administered in the setting of invasive procedures in the prevention of infective endocarditis in high-risk patients. Moreover, previous observational studies that examined the association of nondental invasive procedures with the risk of infective endocarditis have been limited by inadequate sample size. They have typically focused on a few potential at-risk surgical and nonsurgical invasive procedures. However, recent investigations from Sweden and England that used nationwide databases and demonstrated an association between nondental invasive procedures, and the subsequent development of infective endocarditis (in particular, in high-risk patients with infective endocarditis) prompted the development of the current science advisory.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37795631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37795631</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001180>10.1161/CIR.0000000000001180</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37795631</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Larry M Baddour</dc:creator>
<dc:creator>Imre Janszky</dc:creator>
<dc:creator>Martin H Thornhill</dc:creator>
<dc:creator>Zerelda Esquer Garrigos</dc:creator>
<dc:creator>Daniel C DeSimone</dc:creator>
<dc:creator>Karen Welty-Wolf</dc:creator>
<dc:creator>Annette L Baker</dc:creator>
<dc:creator>Pei-Ni Jone</dc:creator>
<dc:creator>Bernard Prendergast</dc:creator>
<dc:creator>Mark J Dayer</dc:creator>
<dc:creator>American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts) and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Nondental Invasive Procedures and Risk of Infective Endocarditis: Time for a Revisit: A Science Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:37795631</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001180</dc:identifier>
</item>
<item>
<title>Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVRIII Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37795623/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: By 12 years after the Norwood operation, shunt type has minimal association with RVEF, peak Vo(2), complication rates, and transplant-free survival. RVEF is preserved among the subgroup of survivors who underwent CMR assessment. Low transplant-free survival, poor exercise performance, and accruing morbidities highlight the need for innovative strategies to improve long-term outcomes in patients with hypoplastic left heart syndrome.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 5. doi: 10.1161/CIRCULATIONAHA.123.065192. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: In the SVR trial (Single Ventricle Reconstruction), newborns with hypoplastic left heart syndrome were randomly assigned to receive a modified Blalock-Taussig-Thomas shunt (mBTTS) or a right ventricle-to-pulmonary artery shunt (RVPAS) at Norwood operation. Transplant-free survival was superior in the RVPAS group at 1 year, but no longer differed by treatment group at 6 years; both treatment groups had accumulated important morbidities. In the third follow-up of this cohort (SVRIII [Long-Term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type]), we measured longitudinal outcomes and their risk factors through 12 years of age.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Annual medical history was collected through record review and telephone interviews. Cardiac magnetic resonance imaging (CMR), echocardiogram, and cycle ergometry cardiopulmonary exercise tests were performed at 10 through 14 years of age among participants with Fontan physiology. Differences in transplant-free survival and complication rates (eg, arrhythmias or protein-losing enteropathy) were identified through 12 years of age. The primary study outcome was right ventricular ejection fraction (RVEF) by CMR, and primary analyses were according to shunt type received. Multivariable linear and Cox regression models were created for RVEF by CMR and post-Fontan transplant-free survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 549 participants enrolled in SVR, 237 of 313 (76%; 60.7% male) transplant-free survivors (mBTTS, 105 of 147; RVPAS, 129 of 161; both, 3 of 5) participated in SVRIII. RVEF by CMR was similar in the shunt groups (RVPAS, 51±9.6 [n=90], and mBTTS, 52±7.4 [n=75]; <i>P</i>=0.43). The RVPAS and mBTTS groups did not differ in transplant-free survival by 12 years of age (163 of 277 [59%] versus 144 of 267 [54%], respectively; <i>P</i>=0.11), percentage predicted peak Vo<sub>2</sub> for age and sex (74±18% [n=91] versus 72±18% [n=84]; <i>P</i>=0.71), or percentage predicted work rate for size and sex (65±20% versus 64±19%; <i>P</i>=0.65). The RVPAS versus mBTTS group had a higher cumulative incidence of protein-losing enteropathy (5% versus 2%; <i>P</i>=0.04) and of catheter interventions (14 versus 10 per 100 patient-years; <i>P</i>=0.01), but had similar rates of other complications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: By 12 years after the Norwood operation, shunt type has minimal association with RVEF, peak Vo<sub>2</sub>, complication rates, and transplant-free survival. RVEF is preserved among the subgroup of survivors who underwent CMR assessment. Low transplant-free survival, poor exercise performance, and accruing morbidities highlight the need for innovative strategies to improve long-term outcomes in patients with hypoplastic left heart syndrome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT00115934.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37795623/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37795623</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065192>10.1161/CIRCULATIONAHA.123.065192</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37795623</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Caren S Goldberg</dc:creator>
<dc:creator>Felicia Trachtenberg</dc:creator>
<dc:creator>J William Gaynor</dc:creator>
<dc:creator>William T Mahle</dc:creator>
<dc:creator>Chitra Ravishankar</dc:creator>
<dc:creator>Steven M Schwartz</dc:creator>
<dc:creator>James F Cnota</dc:creator>
<dc:creator>Richard G Ohye</dc:creator>
<dc:creator>Russell Gongwer</dc:creator>
<dc:creator>Michael Taylor</dc:creator>
<dc:creator>Stephen Paridon</dc:creator>
<dc:creator>Peter C Frommelt</dc:creator>
<dc:creator>Katherine Afton</dc:creator>
<dc:creator>Andrew M Atz</dc:creator>
<dc:creator>Kristin M Burns</dc:creator>
<dc:creator>Jon A Detterich</dc:creator>
<dc:creator>Kevin D Hill</dc:creator>
<dc:creator>Antonio G Cabrera</dc:creator>
<dc:creator>Alan B Lewis</dc:creator>
<dc:creator>Christian Pizarro</dc:creator>
<dc:creator>Amee Shah</dc:creator>
<dc:creator>Binu Sharma</dc:creator>
<dc:creator>Jane W Newburger</dc:creator>
<dc:creator>Pediatric Heart Network Investigators</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVRIII Study</dc:title>
<dc:identifier>pmid:37795623</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065192</dc:identifier>
</item>
<item>
<title>Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37795617/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: For patients with angina and no obstructive coronary arteries, a diagnosis informed by invasive functional assessment had no effect on long-term angina burden, whereas treatment satisfaction improved.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 5. doi: 10.1161/CIRCULATIONAHA.123.064751. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: We investigated the usefulness of invasive coronary function testing to diagnose the cause of angina in patients with no obstructive coronary arteries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Outpatients referred for coronary computed tomography angiography in 3 hospitals in the United Kingdom were prospectively screened. After coronary computed tomography angiography, patients with unobstructed coronary arteries, and who consented, underwent invasive endotyping. The diagnostic assessments included coronary angiography, fractional flow reserve (patient excluded if ≤0.80), and, for those without obstructive coronary artery disease, coronary flow reserve (abnormal &lt;2.0), index of microvascular resistance (abnormal ≥25), and intracoronary infusion of acetylcholine (0.182, 1.82, and 18.2 μg/mL; 2 mL/min for 2 minutes) to assess for microvascular and coronary spasm. Participants were randomly assigned to disclosure of the results of the coronary function tests to the invasive cardiologist (intervention group) or nondisclosure (control group, blinded). In the control group, a diagnosis of vasomotor angina was based on medical history, noninvasive tests, and coronary angiography. The primary outcome was the between-group difference in the reclassification rate of the initial diagnosis on the basis of coronary computed tomography angiography versus the final diagnosis after invasive endotyping. The Seattle Angina Questionnaire summary score and Treatment Satisfaction Questionnaire for Medication were secondary outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 322 eligible patients, 250 (77.6%) underwent invasive endotyping; 19 (7.6%) had obstructive coronary disease, 127 (55.0%) had microvascular angina, 27 (11.7%) had vasospastic angina, 17 (7.4%) had both, and 60 (26.0%) had no abnormality. A total of 231 patients (mean age, 55.7 years; 64.5% women) were randomly assigned and followed up (median duration, 19.9 [12.6-26.9] months). The clinician diagnosed vasomotor angina in 51 (44.3%) patients in the intervention group and in 55 (47.4%) patients in the control group. After randomization, patients in the intervention group were 4-fold (odds ratio, 4.05 [95% CI, 2.32-7.24]; <i>P</i>&lt;0.001) more likely to be diagnosed with a coronary vasomotor disorder; the frequency of this diagnosis increased to 76.5%. The frequency of normal coronary function (ie, no vasomotor disorder) was not different between the groups before randomization (51.3% versus 50.9%) but was reduced in the intervention group after randomization (23.5% versus 50.9%, <i>P</i>&lt;0.001). At 6 and 12 months, the Seattle Angina Questionnaire summary score in the intervention versus control groups was 59.2±24.2 (2.3±16.2 change from baseline) versus 60.4±23.9 (4.6±16.4 change) and 63.7±23.5 (4.7±14.7 change) versus 66.0±19.3 (7.9±17.1 change), respectively, and not different between groups (global <i>P</i>=0.36). Compared with the control group, global treatment satisfaction was higher in the intervention group at 12 months (69.9±22.8 versus 61.7±26.9, <i>P</i>=0.013).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with angina and no obstructive coronary arteries, a diagnosis informed by invasive functional assessment had no effect on long-term angina burden, whereas treatment satisfaction improved.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT03477890.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37795617/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37795617</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064751>10.1161/CIRCULATIONAHA.123.064751</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37795617</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Novalia P Sidik</dc:creator>
<dc:creator>Bethany Stanley</dc:creator>
<dc:creator>Robert Sykes</dc:creator>
<dc:creator>Andrew J Morrow</dc:creator>
<dc:creator>Conor P Bradley</dc:creator>
<dc:creator>Michael McDermott</dc:creator>
<dc:creator>Thomas J Ford</dc:creator>
<dc:creator>Giles Roditi</dc:creator>
<dc:creator>Allister Hargreaves</dc:creator>
<dc:creator>David Stobo</dc:creator>
<dc:creator>Jacqueline Adams</dc:creator>
<dc:creator>John Byrne</dc:creator>
<dc:creator>Ahmed Mahrous</dc:creator>
<dc:creator>Robin Young</dc:creator>
<dc:creator>David Carrick</dc:creator>
<dc:creator>Ross McGeoch</dc:creator>
<dc:creator>David Corcoran</dc:creator>
<dc:creator>Ninian N Lang</dc:creator>
<dc:creator>Robert Heggie</dc:creator>
<dc:creator>Olivia Wu</dc:creator>
<dc:creator>Margaret B McEntegart</dc:creator>
<dc:creator>Alex McConnachie</dc:creator>
<dc:creator>Colin Berry</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:37795617</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064751</dc:identifier>
</item>
<item>
<title>Auditory stimulation of sleep slow waves enhances left ventricular function in humans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37794725/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 5:ehad630. doi: 10.1093/eurheartj/ehad630. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37794725/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37794725</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad630>10.1093/eurheartj/ehad630</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37794725</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Stephanie Huwiler</dc:creator>
<dc:creator>Manuel Carro-Domínguez</dc:creator>
<dc:creator>Fabia M Stich</dc:creator>
<dc:creator>Rossella Sala</dc:creator>
<dc:creator>Florent Aziri</dc:creator>
<dc:creator>Anna Trippel</dc:creator>
<dc:creator>Tabea Ryf</dc:creator>
<dc:creator>Susanne Markendorf</dc:creator>
<dc:creator>David Niederseer</dc:creator>
<dc:creator>Philipp Bohm</dc:creator>
<dc:creator>Gloria Stoll</dc:creator>
<dc:creator>Lily Laubscher</dc:creator>
<dc:creator>Jeivicaa Thevan</dc:creator>
<dc:creator>Christina M Spengler</dc:creator>
<dc:creator>Joanna Gawinecka</dc:creator>
<dc:creator>Elena Osto</dc:creator>
<dc:creator>Reto Huber</dc:creator>
<dc:creator>Nicole Wenderoth</dc:creator>
<dc:creator>Christian Schmied</dc:creator>
<dc:creator>Caroline Lustenberger</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Auditory stimulation of sleep slow waves enhances left ventricular function in humans</dc:title>
<dc:identifier>pmid:37794725</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad630</dc:identifier>
</item>
<item>
<title>Medicine at the dawn of the metaclinical era</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37794638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 5:ehad599. doi: 10.1093/eurheartj/ehad599. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37794638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37794638</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad599>10.1093/eurheartj/ehad599</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37794638</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Panos E Vardas</dc:creator>
<dc:creator>Emmanouil P Vardas</dc:creator>
<dc:creator>Stylianos Tzeis</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Medicine at the dawn of the metaclinical era</dc:title>
<dc:identifier>pmid:37794638</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad599</dc:identifier>
</item>
<item>
<title>When technology innovation is the only path to treat patients in economic crisis countries: the Syrian experience</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37794637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 5:ehad634. doi: 10.1093/eurheartj/ehad634. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37794637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37794637</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad634>10.1093/eurheartj/ehad634</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37794637</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Amr Abdin</dc:creator>
<dc:creator>Asim Katbeh</dc:creator>
<dc:creator>Yassin Bani Marjeh</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>When technology innovation is the only path to treat patients in economic crisis countries: the Syrian experience</dc:title>
<dc:identifier>pmid:37794637</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad634</dc:identifier>
</item>
<item>
<title>Towards personalized cardiovascular care: Global Registry of Acute Coronary Events 3.0 score heralds artificial intelligence era</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37794616/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 5:ehad597. doi: 10.1093/eurheartj/ehad597. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37794616/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37794616</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad597>10.1093/eurheartj/ehad597</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37794616</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Florian A Wenzl</dc:creator>
<dc:creator>Keith A A Fox</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Towards personalized cardiovascular care: Global Registry of Acute Coronary Events 3.0 score heralds artificial intelligence era</dc:title>
<dc:identifier>pmid:37794616</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad597</dc:identifier>
</item>
<item>
<title>Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37794590/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the targeted chromosome, including in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 27:S0092-8674(23)00975-3. doi: 10.1016/j.cell.2023.08.041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the targeted chromosome, including in preclinical chimeric antigen receptor T cells. T cells with chromosome loss persisted for weeks in culture, implying the potential to interfere with clinical use. A modified cell manufacturing process, employed in our first-in-human clinical trial of Cas9-engineered T cells (NCT03399448), reduced chromosome loss while largely preserving genome editing efficacy. Expression of p53 correlated with protection from chromosome loss observed in this protocol, suggesting both a mechanism and strategy for T cell engineering that mitigates this genotoxicity in the clinic.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37794590/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37794590</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.041>10.1016/j.cell.2023.08.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37794590</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Connor A Tsuchida</dc:creator>
<dc:creator>Nadav Brandes</dc:creator>
<dc:creator>Raymund Bueno</dc:creator>
<dc:creator>Marena Trinidad</dc:creator>
<dc:creator>Thomas Mazumder</dc:creator>
<dc:creator>Bingfei Yu</dc:creator>
<dc:creator>Byungjin Hwang</dc:creator>
<dc:creator>Christopher Chang</dc:creator>
<dc:creator>Jamin Liu</dc:creator>
<dc:creator>Yang Sun</dc:creator>
<dc:creator>Caitlin R Hopkins</dc:creator>
<dc:creator>Kevin R Parker</dc:creator>
<dc:creator>Yanyan Qi</dc:creator>
<dc:creator>Laura Hofman</dc:creator>
<dc:creator>Ansuman T Satpathy</dc:creator>
<dc:creator>Edward A Stadtmauer</dc:creator>
<dc:creator>Jamie H D Cate</dc:creator>
<dc:creator>Justin Eyquem</dc:creator>
<dc:creator>Joseph A Fraietta</dc:creator>
<dc:creator>Carl H June</dc:creator>
<dc:creator>Howard Y Chang</dc:creator>
<dc:creator>Chun Jimmie Ye</dc:creator>
<dc:creator>Jennifer A Doudna</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells</dc:title>
<dc:identifier>pmid:37794590</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.041</dc:identifier>
</item>
<item>
<title>SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37794589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>Regulation of viral RNA biogenesis is fundamental to productive SARS-CoV-2 infection. To characterize host RNA-binding proteins (RBPs) involved in this process, we biochemically identified proteins bound to genomic and subgenomic SARS-CoV-2 RNAs. We find that the host protein SND1 binds the 5' end of negative-sense viral RNA and is required for SARS-CoV-2 RNA synthesis. SND1-depleted cells form smaller replication organelles and display diminished virus growth kinetics. We discover that NSP9, a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 28:S0092-8674(23)00980-7. doi: 10.1016/j.cell.2023.09.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Regulation of viral RNA biogenesis is fundamental to productive SARS-CoV-2 infection. To characterize host RNA-binding proteins (RBPs) involved in this process, we biochemically identified proteins bound to genomic and subgenomic SARS-CoV-2 RNAs. We find that the host protein SND1 binds the 5' end of negative-sense viral RNA and is required for SARS-CoV-2 RNA synthesis. SND1-depleted cells form smaller replication organelles and display diminished virus growth kinetics. We discover that NSP9, a viral RBP and direct SND1 interaction partner, is covalently linked to the 5' ends of positive- and negative-sense RNAs produced during infection. These linkages occur at replication-transcription initiation sites, consistent with NSP9 priming viral RNA synthesis. Mechanistically, SND1 remodels NSP9 occupancy and alters the covalent linkage of NSP9 to initiating nucleotides in viral RNA. Our findings implicate NSP9 in the initiation of SARS-CoV-2 RNA synthesis and unravel an unsuspected role of a cellular protein in orchestrating viral RNA production.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37794589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37794589</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.002>10.1016/j.cell.2023.09.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37794589</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Nora Schmidt</dc:creator>
<dc:creator>Sabina Ganskih</dc:creator>
<dc:creator>Yuanjie Wei</dc:creator>
<dc:creator>Alexander Gabel</dc:creator>
<dc:creator>Sebastian Zielinski</dc:creator>
<dc:creator>Hasmik Keshishian</dc:creator>
<dc:creator>Caleb A Lareau</dc:creator>
<dc:creator>Liv Zimmermann</dc:creator>
<dc:creator>Jana Makroczyova</dc:creator>
<dc:creator>Cadence Pearce</dc:creator>
<dc:creator>Karsten Krey</dc:creator>
<dc:creator>Thomas Hennig</dc:creator>
<dc:creator>Sebastian Stegmaier</dc:creator>
<dc:creator>Lambert Moyon</dc:creator>
<dc:creator>Marc Horlacher</dc:creator>
<dc:creator>Simone Werner</dc:creator>
<dc:creator>Jens Aydin</dc:creator>
<dc:creator>Marco Olguin-Nava</dc:creator>
<dc:creator>Ramya Potabattula</dc:creator>
<dc:creator>Anuja Kibe</dc:creator>
<dc:creator>Lars Dölken</dc:creator>
<dc:creator>Redmond P Smyth</dc:creator>
<dc:creator>Neva Caliskan</dc:creator>
<dc:creator>Annalisa Marsico</dc:creator>
<dc:creator>Christine Krempl</dc:creator>
<dc:creator>Jochen Bodem</dc:creator>
<dc:creator>Andreas Pichlmair</dc:creator>
<dc:creator>Steven A Carr</dc:creator>
<dc:creator>Petr Chlanda</dc:creator>
<dc:creator>Florian Erhard</dc:creator>
<dc:creator>Mathias Munschauer</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9</dc:title>
<dc:identifier>pmid:37794589</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.002</dc:identifier>
</item>
<item>
<title>Retraction of: Cardiovascular risk profile of a young adult population with high risk for obstructive sleep apnea screened by Stop-Bang and Epworth sleepiness scale in a primary health care unit</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37793986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 5:ehad580. doi: 10.1093/eurheartj/ehad580. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37793986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37793986</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad580>10.1093/eurheartj/ehad580</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37793986</guid>
<pubDate>Wed, 04 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Retraction of: Cardiovascular risk profile of a young adult population with high risk for obstructive sleep apnea screened by Stop-Bang and Epworth sleepiness scale in a primary health care unit</dc:title>
<dc:identifier>pmid:37793986</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad580</dc:identifier>
</item>
<item>
<title>KDIGO or UACR: Which Is Key in Affecting Efficacy of SGLT2i in Patients With HF?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37793755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 10;82(15):e135-e136. doi: 10.1016/j.jacc.2023.06.051.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37793755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37793755</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.051>10.1016/j.jacc.2023.06.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37793755</guid>
<pubDate>Wed, 04 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Xiaoqun Xu</dc:creator>
<dc:creator>Houyong Zhu</dc:creator>
<dc:creator>Long Cai</dc:creator>
<dc:creator>Tielong Chen</dc:creator>
<dc:creator>Kaiqing Lin</dc:creator>
<dc:date>2023-10-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>KDIGO or UACR: Which Is Key in Affecting Efficacy of SGLT2i in Patients With HF?</dc:title>
<dc:identifier>pmid:37793755</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.051</dc:identifier>
</item>
<item>
<title>Empagliflozin in Patients With Heart Failure: Efficacy and Safety Concerns Across Kidney Risk Categories</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37793754/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 10;82(15):e133. doi: 10.1016/j.jacc.2023.06.052.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37793754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37793754</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.052>10.1016/j.jacc.2023.06.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37793754</guid>
<pubDate>Wed, 04 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Yuzuru Ohshiro</dc:creator>
<dc:date>2023-10-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Empagliflozin in Patients With Heart Failure: Efficacy and Safety Concerns Across Kidney Risk Categories</dc:title>
<dc:identifier>pmid:37793754</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.052</dc:identifier>
</item>
<item>
<title>Childhood Screening for Familial Hypercholesterolemia: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37793753/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>Screening for familial hypercholesterolemia (FH) in childhood remains controversial. Existing guidelines offer practitioners conflicting advice despite generally agreeing on the evidence and areas in which evidence is lacking, including a lack of long-term clinical trials demonstrating coronary event reduction as a result of screening and long-term data on statin side effects. A limitation of existing evidence-based frameworks is reliance on 1 evidence grading system to determine...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 10;82(15):1558-1563. doi: 10.1016/j.jacc.2023.07.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Screening for familial hypercholesterolemia (FH) in childhood remains controversial. Existing guidelines offer practitioners conflicting advice despite generally agreeing on the evidence and areas in which evidence is lacking, including a lack of long-term clinical trials demonstrating coronary event reduction as a result of screening and long-term data on statin side effects. A limitation of existing evidence-based frameworks is reliance on 1 evidence grading system to determine recommendations. However, rigorous evidence evaluation alternatives relevant to FH exist. FH is considered a tier 1 genetic condition, meaning that identification and treatment will improve health outcomes among those affected. Elevated low-density lipoprotein cholesterol, the primary consequence of FH, can be considered causal for atherosclerosis and coronary heart disease. Incorporating these concepts into existing evidence pathways allows the inclusion of surrogate clinical trial outcomes (low-density lipoprotein cholesterol reduction and atherosclerosis regression) and observational data on medication safety, strengthening the evidence for pediatric screening for FH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37793753/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37793753</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.028>10.1016/j.jacc.2023.07.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37793753</guid>
<pubDate>Wed, 04 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Samuel S Gidding</dc:creator>
<dc:date>2023-10-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Childhood Screening for Familial Hypercholesterolemia: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37793753</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.028</dc:identifier>
</item>
<item>
<title>Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37793752/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>Stroke is a devastating condition with significant morbidity and mortality worldwide. Antithrombotic therapy plays a crucial role in both primary and secondary prevention of stroke events. Single or dual antiplatelet therapy is generally preferred in cases of large-artery atherosclerosis and small-vessel disease, whereas anticoagulation is recommended in conditions of blood stasis or hypercoagulable states that mostly result in red thrombi. However, the benefit of antithrombotic therapies must...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 10;82(15):1538-1557. doi: 10.1016/j.jacc.2023.07.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Stroke is a devastating condition with significant morbidity and mortality worldwide. Antithrombotic therapy plays a crucial role in both primary and secondary prevention of stroke events. Single or dual antiplatelet therapy is generally preferred in cases of large-artery atherosclerosis and small-vessel disease, whereas anticoagulation is recommended in conditions of blood stasis or hypercoagulable states that mostly result in red thrombi. However, the benefit of antithrombotic therapies must be weighed against the increased risk of bleeding, which can pose significant challenges in the pharmacological management of this condition. This review provides a comprehensive summary of the currently available evidence on antithrombotic therapy for ischemic stroke and outlines an updated therapeutic algorithm to support physicians in tailoring the strategy to the individual patient and the underlying mechanism of stroke.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37793752/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37793752</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.025>10.1016/j.jacc.2023.07.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37793752</guid>
<pubDate>Wed, 04 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Antonio Greco</dc:creator>
<dc:creator>Giovanni Occhipinti</dc:creator>
<dc:creator>Daniele Giacoppo</dc:creator>
<dc:creator>Federica Agnello</dc:creator>
<dc:creator>Claudio Laudani</dc:creator>
<dc:creator>Marco Spagnolo</dc:creator>
<dc:creator>Maria Sara Mauro</dc:creator>
<dc:creator>Carla Rochira</dc:creator>
<dc:creator>Simone Finocchiaro</dc:creator>
<dc:creator>Placido Maria Mazzone</dc:creator>
<dc:creator>Denise Cristiana Faro</dc:creator>
<dc:creator>Davide Landolina</dc:creator>
<dc:creator>Nicola Ammirabile</dc:creator>
<dc:creator>Antonino Imbesi</dc:creator>
<dc:creator>Carmelo Raffo</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:date>2023-10-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37793752</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.025</dc:identifier>
</item>
<item>
<title>Staging of Fabry Cardiomyopathy by Echocardiography: Back to the Roots?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37793751/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 10;82(15):1535-1537. doi: 10.1016/j.jacc.2023.08.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37793751/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37793751</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.009>10.1016/j.jacc.2023.08.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37793751</guid>
<pubDate>Wed, 04 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Gere Sunder-Plassmann</dc:creator>
<dc:creator>Senta Graf</dc:creator>
<dc:creator>Constantin Gatterer</dc:creator>
<dc:date>2023-10-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Staging of Fabry Cardiomyopathy by Echocardiography: Back to the Roots?</dc:title>
<dc:identifier>pmid:37793751</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.009</dc:identifier>
</item>
<item>
<title>Prognostic Implications of the Extent of Cardiac Damage in Patients With Fabry Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37793750/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In FD patients, a novel staging classification of cardiac damage, evaluated by echocardiography, is strongly associated with cardiovascular outcomes and may be helpful to refine risk stratification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 10;82(15):1524-1534. doi: 10.1016/j.jacc.2023.07.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: There is limited evidence on the risk stratification of cardiovascular outcomes in patients with Fabry disease (FD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to classify FD patients into disease stages, based on the extent of the cardiac damage evaluated by echocardiography, and to assess their prognostic impact in a multicenter cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with FD from 5 Italian referral centers were categorized into 4 stages: stage 0, no cardiac involvement; stage 1, left ventricular (LV) hypertrophy (LV maximal wall thickness >;12 mm); stage 2, left atrium (LA) enlargement (LA volume index >;34 mL/m<sup>2</sup>); stage 3, ventricular impairment (LV ejection fraction &lt;50% or E/e' ≥15 or TAPSE &lt;17 mm). The study endpoint was the composite of all-cause death, hospitalization for heart failure, new-onset atrial fibrillation, major bradyarrhythmias or tachyarrhythmias, and ischemic stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 314 patients were included. Among them, 174 (56%) were classified as stage 0, 41 (13%) as stage 1, 57 (18%) as stage 2 and 42 (13%) as stage 3. A progressive increase in the composite event rate at 8 years was observed with worsening stages of cardiac damage (log-rank P &lt; 0.001). On multivariable Cox regression analysis, the staging was independently associated with the risk of cardiovascular events (HR: 2.086 per 1-stage increase; 95% CI: 1.487-2.927; P &lt; 0.001). Notably, cardiac staging demonstrated a stronger and additive prognostic value, as compared with the degree of LV hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In FD patients, a novel staging classification of cardiac damage, evaluated by echocardiography, is strongly associated with cardiovascular outcomes and may be helpful to refine risk stratification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37793750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37793750</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.026>10.1016/j.jacc.2023.07.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37793750</guid>
<pubDate>Wed, 04 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Maria Chiara Meucci</dc:creator>
<dc:creator>Rosa Lillo</dc:creator>
<dc:creator>Annamaria Del Franco</dc:creator>
<dc:creator>Emanuele Monda</dc:creator>
<dc:creator>Giulia Iannaccone</dc:creator>
<dc:creator>Riccardo Baldassarre</dc:creator>
<dc:creator>Federico Di Nicola</dc:creator>
<dc:creator>Vanda Parisi</dc:creator>
<dc:creator>Antonella Lombardo</dc:creator>
<dc:creator>Letizia Spinelli</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>Maurizio Pieroni</dc:creator>
<dc:creator>Antonio Pisani</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Guido Iaccarino</dc:creator>
<dc:creator>Giuseppe Limongelli</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Francesca Graziani</dc:creator>
<dc:date>2023-10-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prognostic Implications of the Extent of Cardiac Damage in Patients With Fabry Disease</dc:title>
<dc:identifier>pmid:37793750</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.026</dc:identifier>
</item>
<item>
<title>Donation After Circulatory Death: Shifting the Paradigm in Heart Transplantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37793749/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 10;82(15):1521-1523. doi: 10.1016/j.jacc.2023.08.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37793749/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37793749</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.025>10.1016/j.jacc.2023.08.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37793749</guid>
<pubDate>Wed, 04 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Sean P Pinney</dc:creator>
<dc:creator>Maria Rosa Costanzo</dc:creator>
<dc:date>2023-10-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Donation After Circulatory Death: Shifting the Paradigm in Heart Transplantation</dc:title>
<dc:identifier>pmid:37793749</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.025</dc:identifier>
</item>
<item>
<title>Outcomes of Heart Transplant Donation After Circulatory Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37793748/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231006041047&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In the largest single-center comparison of DCD and DBD heart transplantations to date, outcomes among DCD recipients are noninferior to those of DBD recipients. This study adds to the published data supporting DCD donors as a safe means to expand the heart donor pool.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 10;82(15):1512-1520. doi: 10.1016/j.jacc.2023.08.006.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart transplantation using donation after circulatory death (DCD) allografts is increasingly common, expanding the donor pool and reducing transplant wait times. However, data remain limited on clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We sought to compare 6-month and 1-year clinical outcomes between recipients of DCD hearts, most of them recovered with the use of normothermic regional perfusion (NRP), and recipients of donation after brain death (DBD) hearts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a single-center retrospective observational study of all adult heart-only transplants from January 2020 to January 2023. Recipient and donor data were abstracted from medical records and the United Network for Organ Sharing registry, respectively. Survival analysis and Cox regression were used to compare the groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the study period, 385 adults (median age 57.4 years [IQR: 48.0-63.7 years]) underwent heart-only transplantation, including 122 (32%) from DCD donors, 83% of which were recovered with the use of NRP. DCD donors were younger and had fewer comorbidities than DBD donors. DCD recipients were less often hospitalized before transplantation and less likely to require pretransplantation temporary mechanical circulatory support compared with DBD recipients. There were no significant differences between groups in 1-year survival, incidence of severe primary graft dysfunction, treated rejection during the first year, or likelihood of cardiac allograft vasculopathy at 1 year after transplantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the largest single-center comparison of DCD and DBD heart transplantations to date, outcomes among DCD recipients are noninferior to those of DBD recipients. This study adds to the published data supporting DCD donors as a safe means to expand the heart donor pool.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37793748/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231006041047&v=2.17.9.post6+86293ac">37793748</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.006>10.1016/j.jacc.2023.08.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37793748</guid>
<pubDate>Wed, 04 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Hasan K Siddiqi</dc:creator>
<dc:creator>John Trahanas</dc:creator>
<dc:creator>Meng Xu</dc:creator>
<dc:creator>Quinn Wells</dc:creator>
<dc:creator>Eric Farber-Eger</dc:creator>
<dc:creator>Chetan Pasrija</dc:creator>
<dc:creator>Kaushik Amancherla</dc:creator>
<dc:creator>Alexandra Debose-Scarlett</dc:creator>
<dc:creator>D Marshall Brinkley</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Jonathan N Menachem</dc:creator>
<dc:creator>Henry Ooi</dc:creator>
<dc:creator>Dawn Pedrotty</dc:creator>
<dc:creator>Lynn Punnoose</dc:creator>
<dc:creator>Aniket S Rali</dc:creator>
<dc:creator>Suzanne Sacks</dc:creator>
<dc:creator>Mark Wigger</dc:creator>
<dc:creator>Sandip Zalawadiya</dc:creator>
<dc:creator>William McMaster</dc:creator>
<dc:creator>Steven Devries</dc:creator>
<dc:creator>Ashish Shah</dc:creator>
<dc:creator>Kelly Schlendorf</dc:creator>
<dc:date>2023-10-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Outcomes of Heart Transplant Donation After Circulatory Death</dc:title>
<dc:identifier>pmid:37793748</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.006</dc:identifier>
</item>





























</channel>
</rss>